Novo Nordisk

Rigel in-licensed exclusive, worldwide rights to develop, manufacture, and commercialize olutasidenib, an oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor, in all indications, including relapsed/refractory acute myeloid leukemia and other malignancies.

Olutasidenib was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022.  Under the terms of the agreement, Novo Nordisk received an upfront payment and is eligible to receive additional near-term regulatory, approval, commercial sale milestones, and tiered royalties on sales.

Rigel is responsible for the commercialization of olutasidenib in the U.S., and intends to work with partners to further develop and commercialize olutasidenib outside the U.S.

Click here for Press Release